112-LB: Melatonin and DPP-IV Inhibitor: A Novel Combinatorial Approach for ß-Cell Regeneration

Progressive deterioration of β-cell function and mass is a central parameter to the development of type-1/2 diabetes (T1/2D). Over the last decade, many studies have explored the potential benefits of incretin-based therapies on β-cell preservation and/or regeneration. In this context, DPP-IV inhibitor is known to improve GLP-1 and GIP longevity besides increasing β-cell mass. Melatonin, a pineal hormone is shown to ameliorate oxidative stress...